SEC ownership of Immunocore Holdings plc

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001671927.

Comparable stake leader

WELLINGTON MANAGEMENT GROUP LLP

Disclosed value leader

WELLINGTON MANAGEMENT GROUP LLP

Comparable rows

50/50

Latest evidence

30 Jun 2026

Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
50 of 50
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
WELLINGTON MANAGEMENT GROUP LLP
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
30 Jun 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001671927
Issuer location
Oxfordshire, United Kingdom

Ownership snapshot

Top shareholders of Immunocore Holdings plc (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
WELLINGTON MANAGEMENT GRO...
Disclosed value leader
WELLINGTON MANAGEMENT GRO...
Comparable rows
50/50
Latest evidence
30 Jun 2026
13D/G 13F 3/4/5 Lead comparable stake: 12% 13D/G row: WELLINGTON MANAGEMENT GROUP LLP Showing 1-8 of 50 holder rows.

Quick read

WELLINGTON MANAGEMENT GROUP LLP leads the comparable SEC ownership view at 12%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens WELLINGTON MANAGEMENT GROUP LLP's linked filing trail.
Comparable ownership Top 5
WELLINGTON MANAGEMENT GROUP LLP 12%
FMR LLC 8.8%
Jallal Bahija 8.2%
PRIMECAP MANAGEMENT CO/CA/ 7.5%
Bellevue Group AG 5.6%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
WELLINGTON MANAGEMENT GROUP LLP
13D/G 13F
Company
12%
$190,355,150
5,959,773 shares
+$26,410,388 30 Jun 2026
FMR LLC
13D/G 13F
Company
8.8%
$137,573,437
4,307,246 shares
$0 30 Jun 2026
Jallal Bahija
13D/G 3/4/5
CHIEF EXECUTIVE OFFICER, Director
8.2%
$135,513,072
4,493,139 shares
$0 31 Dec 2024
PRIMECAP MANAGEMENT CO/CA/
13D/G 13F
Company
7.5%
$130,443,852
3,772,234 shares
+$38,165,393 30 Jun 2025
Bellevue Group AG
13D/G 13F
Company
5.6%
$101,607,853
2,796,803 shares
$0 20 Aug 2025
TANG CAPITAL MANAGEMENT LLC
13D/G 13F
Company
5.2%
$94,662,520
2,605,608 shares
$0 17 Oct 2025
T. Rowe Price Investment Management, Inc.
13D/G
3.7%
$60,417,704
1,891,600 shares
-$36,740,710 31 Mar 2026
Vestal Point Capital, LP
13D/G 13F
Company
3.5%
$57,492,000
1,800,000 shares
-$30,881,764 30 Jun 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to selling over the last 12 months. Net value: -$10,449,605.

Buys
$0
Insiders: 0
Sells
$10,449,605
Insiders: 4
Net
-$10,449,605
Shares: -279,095
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 279,095
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 51,050 $0 $1,903,831 -$1,903,831
9-12 0 228,045 $0 $8,545,775 -$8,545,775

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-15 of 15 reporting-owner rows connected to Immunocore Holdings plc. Open a relationship link for the CIK-to-CIK filing trail.

Rows
15
Largest Forms 3/4/5 holder
BAKER BROS. ADVISORS LP
Net 12M change
-$10,449,605
Latest report
27 May 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
BAKER BROS. ADVISORS LP Director $63,379,057 Filing P/S 15 May 2025
Brian di Donato Chief Financial Officer $1,354,946 Mixed 16 Feb 2024
Jallal Bahija CHIEF EXECUTIVE OFFICER, Director $399,296 -$371,184 -48% Filing P/S 17 Feb 2026
David M. Berman Head Of R&D $189,538 -$10,023,491 -98% Filing P/S 17 Feb 2026
Tina Amber St Leger Chief Hr Officer $36,199 -$32,350 -47% Filing P/S 17 Feb 2026
John Goll Svp, Finance & Cao $21,124 -$22,580 -52% Filing P/S 17 Feb 2026
William Pao Director Mixed 27 May 2026
Travis Alan Coy Chief Financial Officer Mixed 17 Feb 2026
John Irving Bell Director Mixed 27 May 2026
Ranjeev Krishana Director Mixed 28 May 2024
Kristine Peterson Director Mixed 27 May 2026
Robert J. Perez Director Mixed 02 Jan 2024
Roy Steven Herbst Director Mixed 27 May 2026
Peter John Ratcliffe Director Mixed 27 May 2026
Siddharth Kaul Director Mixed 27 May 2026

Recent insider transactions for Immunocore Holdings plc

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Peter John Ratcliffe IMCR Share Option (Right to Buy) Award 27,492 27,492 27 May 2026 Direct
Kristine Peterson IMCR Share Option (Right to Buy) Award 27,492 27,492 27 May 2026 Direct
William Pao IMCR Share Option (Right to Buy) Award 27,492 27,492 27 May 2026 Direct
Siddharth Kaul IMCR Share Option (Right to Buy) Award 27,492 27,492 27 May 2026 Direct
Roy Steven Herbst IMCR Share Option (Right to Buy) Award 27,492 27,492 27 May 2026 Direct
John Irving Bell IMCR Share Option (Right to Buy) Award 27,492 27,492 27 May 2026 Direct
Bahija Jallal IMCR Ordinary Shares Sale -48.2% $371,184 $32.35 -11,474 12,343 18 Feb 2026 Direct
John Goll IMCR Ordinary Shares Sale -51.7% $22,580 $32.35 -698 653 18 Feb 2026 Direct
Tina Amber St Leger IMCR Ordinary Shares Sale -47.2% $32,350 $32.35 -1,000 1,119 18 Feb 2026 Direct
David M. Berman IMCR Ordinary Shares Sale -50.4% $192,968 $32.35 -5,965 5,859 18 Feb 2026 Direct
Travis Alan Coy IMCR Employee Share Option (Right to Buy) Award 95,637 95,637 17 Feb 2026 Direct
Travis Alan Coy IMCR Restricted Share Units Award 33,353 33,353 17 Feb 2026 Direct
Bahija Jallal IMCR Ordinary Shares Options Exercise 23,817 23,817 17 Feb 2026 Direct
Bahija Jallal IMCR Employee Share Option (Right to Buy) Award 395,066 395,066 17 Feb 2026 Direct
Bahija Jallal IMCR Restricted Share Units Award 88,573 88,573 17 Feb 2026 Direct
Bahija Jallal IMCR Restricted Share Units Options Exercise -25% -23,817 71,453 17 Feb 2026 Direct
John Goll IMCR Ordinary Shares Options Exercise 1,351 1,351 17 Feb 2026 Direct
John Goll IMCR Employee Share Option (Right to Buy) Award 21,252 21,252 17 Feb 2026 Direct
John Goll IMCR Restricted Share Units Award 7,411 7,411 17 Feb 2026 Direct
John Goll IMCR Restricted Share Units Options Exercise -25% -1,351 4,054 17 Feb 2026 Direct
Tina Amber St Leger IMCR Ordinary Shares Options Exercise 2,119 2,119 17 Feb 2026 Direct
Tina Amber St Leger IMCR Restricted Share Units Options Exercise -25% -2,119 6,357 17 Feb 2026 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 11,824 11,824 17 Feb 2026 Direct
David M. Berman IMCR Restricted Share Units Options Exercise -25% -11,824 35,473 17 Feb 2026 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $22,960 $40.14 -572 0 05 Dec 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 572 572 05 Dec 2025 Direct
David M. Berman IMCR Employee Share Option (Right to Buy) Options Exercise -4.61% -572 11,832 05 Dec 2025 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $1,261,789 $40.26 -31,341 0 04 Dec 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 31,341 31,341 04 Dec 2025 Direct
David M. Berman IMCR Employee Share Option (Right to Buy) Options Exercise -71.6% -31,341 12,404 04 Dec 2025 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $221,337 $40.09 -5,521 0 28 Nov 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 5,521 5,521 28 Nov 2025 Direct
David M. Berman IMCR Employee Share Option (Right to Buy) Options Exercise -11.2% -5,521 43,745 28 Nov 2025 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $2,784,488 $40.12 -69,404 0 26 Nov 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 69,404 69,404 26 Nov 2025 Direct
David M. Berman IMCR Employee Share Option (Right to Buy) Options Exercise -58.5% -69,404 49,266 26 Nov 2025 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $721,341 $40.03 -18,020 0 25 Nov 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 18,020 18,020 25 Nov 2025 Direct
David M. Berman IMCR Employee Share Option (Right to Buy) Options Exercise -13.2% -18,020 118,670 25 Nov 2025 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $4,000 $40.00 -100 0 24 Nov 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 100 100 24 Nov 2025 Direct
David M. Berman IMCR Employee Share Option (Right to Buy) Options Exercise -0.07% -100 136,690 24 Nov 2025 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $2,178,940 $35.23 -61,849 0 30 Sep 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 61,849 61,849 30 Sep 2025 Direct
David M. Berman IMCR Employee Share Option (Right to Buy) Options Exercise -31.1% -61,849 136,790 30 Sep 2025 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $7,002 $35.01 -200 0 15 Sep 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 200 200 15 Sep 2025 Direct
David M. Berman IMCR Employee Share Option (Right to Buy) Options Exercise -0.1% -200 198,639 15 Sep 2025 Direct
David M. Berman IMCR Ordinary Shares Sale -100% $803,699 $35.67 -22,532 0 12 Sep 2025 Direct
David M. Berman IMCR Ordinary Shares Options Exercise 22,532 22,532 12 Sep 2025 Direct
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .